Mila Kovacevic

Mila Kovacevic

Auto-generated profile, based on publicly available information

Mila Kovacevic

Institute of Cardiovascular Diseases Vojvodina Sremska Kamenica Serbia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
MKMila Kovacevic
Mila Kovacevic
FBFrancesco Bianchini
Francesco Bianchini
SESameh Elharty
Sameh Elharty
GBGeorge Besis
George Besis
CACristina Aurigemma
Cristina Aurigemma
CTCarlo Trani
Carlo Trani
In humans, the most common anatomic variation of the left main (LM) stem is represented by its distal division in 3 branches (LM trifurcation) instead of 2. LM trifurcation disease accounts for ≈10% to 15% of all LM diseases and is often managed by cardiac surgery. Over the last decades, due to the improvement of interventional material and techniques, percutaneous coronary intervention started gaining acceptance to treat patients with LM disease including those with trifurcated anatomy. Yet, LM trifurcation stenosis with its intrinsic anatomic complexity (3 branches, at least 4 angles, wide variability in branch size and disease) is recognized as a challenging lesion subset for percutaneous coronary intervention. In this review, we summarize available data about LM trifurcation anatomy, its influence on percutaneous coronary intervention feasibility, and the evidence collected regarding the different technical options (including trissing balloon inflation).

5 December 2023 in Platelets
Verified
Journal Article
Open access
MKMila Kovacevic
Mila Kovacevic
GPGraziella Pompei
Graziella Pompei
VKVijay Kunadian
Vijay Kunadian
The older population represents a unique subset of patients due to a higher rate of comorbidities and risk factors, which can lead to a higher rate of ischemic and bleeding events. As a result, older adults are mainly underrepresented or excluded from randomized trials. Although the advancement in the percutaneous coronary intervention field with the development of new technologies, techniques, and potent antiplatelet therapy led to a reduction of ischemic risk, there is still a concern regarding bleeding hazards. Apart from the global utilization of less invasive trans-radial approach and proton pump inhibitors to reduce bleeding risk, proper tailoring of antiplatelet therapy in the older person is imperative. So far, several antiplatelet drugs have been introduced in different clinical scenarios, with dual antiplatelet therapy (combination of acetylsalicylic acid and P2Y12 inhibitor) recommended after percutaneous coronary intervention. The decision on the choice of antiplatelet drug and the DAPT duration is challenging and should be based on the relationship between ischemia and bleeding with the purpose of reducing ischemic events but not at the expense of increased bleeding complications. This is particularly important in the older population, where the evidence is obscure. The main objective of this review is to summarize the available evidence on contemporary antiplatelet therapy and different approaches of de-escalation strategies in older patients after percutaneous coronary intervention.

1 January 2023 in Srpski arhiv za celokupno lekarstvo
Verified
Journal Article
Open access
PDF file
MJMilana Jarakovic
Milana Jarakovic
MPMilovan Petrovic
Milovan Petrovic
DIDragan Ivanisevic
Dragan Ivanisevic
BMBojan Mihajlovic
Bojan Mihajlovic
MKMila Kovacevic
Mila Kovacevic
IPIva Popov
Iva Popov
Introduction/Objective. The optimal percutaneous coronary intervention (PCI) in patients with non-STelevated myocardial infarction (NSTEMI) and multivessel coronary artery disease (CAD) is still not clear. The aim of our study was to examine intrahospital and long-term major adverse cardiovascular and cerebrovascular events (MACCE) in this group of patients. Methods. This retrospective study included 225 patients with NSTEMI and multivessel CAD treated with PCI at the Institute of Cardiovascular Diseases of Vojvodina. Three groups were formed: complete one-stage PCI; complete multi-stage PCI, and culprit-only PCI. We analyzed intrahospital and one-year follow-up MACCE and mortality after three years in all three groups. Results. Complete one-stage PCI was performed in 112 (49.8%), complete multi-stage PCI in 70 (31.3%), and culprit-only PCI in 43 (19.1%) patients. Patients with multi-stage complete PCI had the lowest mortality in comparison with one-stage and culprit-only PCI, both intrahospital (0% vs. 0.9% and 20.9%, respectively, p < 0.0005) and after one year (0% vs. 2.7% and 30.2%, respectively, p < 0.0005) and three years (4.3% vs. 5.4% and 32.6%, respectively, p < 0.0005). There was no significant difference in other MACCE between the groups, both intrahospital and after one year. Conclusion. In our study, multi-stage PCI significantly reduces intrahospital, one-year and three-year follow-up mortality in patients with NSTEMI and multivessel CAD.

24 April 2025 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
Marko AtanaskovićMarko Atanasković
Marko Atanasković
BCBranislav Crnomarković
Branislav Crnomarković
TMTihomir Miljević
Tihomir Miljević
MKMila Kovačević
Mila Kovačević

1 January 2023 in Srce i krvni sudovi
Verified
Journal Article
Open access
PDF file
MNMilan Nedeljković
Milan Nedeljković
DSDragan Sagić
Dragan Sagić
MFMihajlo Farkić
Mihajlo Farkić
DBDarko Boljević
Darko Boljević
SHSaša Hinić
Saša Hinić
BBBranko Beleslin
Branko Beleslin
Aortic stenosis (AS) is the most common valvular disease requiring surgical (SAVR) or transcatheter intervention (TAVI) in Europe and North America. The first TAVI was performed in 2002 in order to treat in-operable patients with AS, and the initial ESC guidelines recommended this procedure in patients with a high risk of SAVR. According to ESC guidelines for the treatment of valvular diseases from 2021, the decision on the treatment modality of AS is defined by the Heart team, and SAVR is recommended in younger patients with a low risk of surgery (<75 years STS-PROM/ EuroScore II8%) or in patients not suitable for surgery. In addition, large randomized clinical studies (PARTNER 3, Evolut Low Risk and NOTION studies) showed that TAVI is also safe in patients with a low operative risk (STS-PROM/EuroScore II<4%), and not inferior to SAVR (UK TAVI trial). The first TAVI procedure in Republic of Serbia was performed on April 22, 2014 during BASIC 8+ Congress. In the period of 2014-2023, 444 TAVI procedures were performed in Republic of Serbia, with exponential increase in in the last 2 years.

5 May 2025 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
AIAlfonso Ielasi
Alfonso Ielasi
RCRodolfo Caminiti
Rodolfo Caminiti
AGArturo Giordano
Arturo Giordano
AHAndreas Holzamer
Andreas Holzamer
GVGiampaolo Vetta
Giampaolo Vetta
MTMaurizio Tespili
Maurizio Tespili